1. Home
  2. FRES vs BCDA Comparison

FRES vs BCDA Comparison

Compare FRES & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRES
  • BCDA
  • Stock Information
  • Founded
  • FRES 2010
  • BCDA N/A
  • Country
  • FRES United States
  • BCDA United States
  • Employees
  • FRES 75
  • BCDA N/A
  • Industry
  • FRES Medical Specialities
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRES Health Care
  • BCDA Health Care
  • Exchange
  • FRES Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • FRES 6.4M
  • BCDA 9.4M
  • IPO Year
  • FRES 2020
  • BCDA N/A
  • Fundamental
  • Price
  • FRES $2.59
  • BCDA $3.11
  • Analyst Decision
  • FRES
  • BCDA Strong Buy
  • Analyst Count
  • FRES 0
  • BCDA 1
  • Target Price
  • FRES N/A
  • BCDA $60.00
  • AVG Volume (30 Days)
  • FRES 10.6K
  • BCDA 100.2K
  • Earning Date
  • FRES 09-17-2024
  • BCDA 08-07-2024
  • Dividend Yield
  • FRES N/A
  • BCDA N/A
  • EPS Growth
  • FRES N/A
  • BCDA N/A
  • EPS
  • FRES N/A
  • BCDA N/A
  • Revenue
  • FRES $2,345,304.00
  • BCDA $468,000.00
  • Revenue This Year
  • FRES N/A
  • BCDA N/A
  • Revenue Next Year
  • FRES N/A
  • BCDA $436.41
  • P/E Ratio
  • FRES N/A
  • BCDA N/A
  • Revenue Growth
  • FRES N/A
  • BCDA N/A
  • 52 Week Low
  • FRES $2.50
  • BCDA $2.62
  • 52 Week High
  • FRES $41.50
  • BCDA $37.80
  • Technical
  • Relative Strength Index (RSI)
  • FRES 34.96
  • BCDA 41.18
  • Support Level
  • FRES $2.56
  • BCDA $2.84
  • Resistance Level
  • FRES $3.40
  • BCDA $3.66
  • Average True Range (ATR)
  • FRES 0.37
  • BCDA 0.31
  • MACD
  • FRES -0.03
  • BCDA 0.11
  • Stochastic Oscillator
  • FRES 7.50
  • BCDA 36.05

About FRES Fresh2 Group Limited

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: